Amazon started $25-a-month weight-loss shots. Kailera IPO'd at $625M.
A new retail floor and a new capital ceiling for the weight-loss drug market, landed in the same week. The price patients pay and the price investors pay, both just reset.
Peptide research, regulation, discovery. Every story links to the peptide it’s about.
RSSA new retail floor and a new capital ceiling for the weight-loss drug market, landed in the same week. The price patients pay and the price investors pay, both just reset.
Tirzepatide produced 22% weight loss vs 15% for semaglutide in a head-to-head trial. The bigger number wins the weight race but comes with a bigger muscle cost. A third hormone may fix it.
A late-stage substudy showed semaglutide lowering an Alzheimer's biological marker in spinal fluid. The same week, a peer-reviewed review mapped three peptide classes already in Alzheimer's trials.
Microsoft researchers pulled every lab-tested AI drug design result into one scorecard. Binders work. Antibodies are inconsistent. Enzymes are harder. One target keeps beating the AI.
New real-world data suggests tirzepatide loses more muscle than semaglutide at matched weight reduction. The next generation of drugs is adding a glucagon receptor to protect muscle.
Svetlana Mojsov identified the active form of GLP-1 in 1983. Every Ozempic, Wegovy, Mounjaro, and Zepbound traces back to her work. Public credit took forty years to catch up.
Orforglipron is the first pill in the Ozempic class. In a two-year diabetes trial of 2,749 adults, it cut deaths by more than half compared to standard insulin therapy.
Twelve peptides came off a restricted list. Seven more, including BPC-157 and TB-500, are going to a July committee vote. Most outlets reported these as one decision. They are not.